Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | BRIP1 Q554Hfs*35 |
Therapy | Olaparib |
Indication/Tumor Type | endometrial serous adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRIP1 Q554Hfs*35 | endometrial serous adenocarcinoma | predicted - sensitive | Olaparib | Case Reports/Case Series | Actionable | In a clinical case study, Lynparza (olaparib) treatment resulted in rapid clinical improvement and an ongoing complete response 9 months after initiation of treatment in a patient with high-grade serous endometrial carcinoma harboring a BRIP1 Q554Hfs*35 mutation, who also harbored other genomic changes consistent with homologous recombination defects including loss of heterozygosity in BRCA2, MAP3K1, PIK3R1, PTCH1, and KDM6A (PMID: 32923896). | 32923896 |
PubMed Id | Reference Title | Details |
---|---|---|
(32923896) | Olaparib Monotherapy for BRIP1-Mutated High-Grade Serous Endometrial Cancer. | Full reference... |